Colistin Nephrotoxicity in Adults: Single Centre Large Series from India
Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect. This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients. Retrospective cohort study. Case record a...
Gespeichert in:
| Veröffentlicht in: | Indian journal of critical care medicine 2017-06, Vol.21 (6), p.350-354 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 6 |
| container_start_page | 350 |
| container_title | Indian journal of critical care medicine |
| container_volume | 21 |
| creator | Ghafur, Abdul Gohel, Swati Devarajan, Vidyalakshmi Raja, T Easow, Jose Raja, M A Sreenivas, Sankar Ramakrishnan, Balasubramaniam Ramakrishnan, T Raman, S G Devaprasad, Dedeepiya Venkatachalam, Balaji Nimmagadda, Ramesh |
| description | Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect.
This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients.
Retrospective cohort study.
Case record analysis of patients who received colistin, in an oncology center in India, between January 2011 and December 2015. Nephrotoxicity was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria.
P < 0.05 was considered as statistically significant.
Out of the 229 patients, 13.1% (30/229) developed abnormal RIFLE. Abnormal RIFLE group (
= 30), in comparison to the normal renal function group (
= 199), had higher number of patients in intensive care unit (ICU) (96% vs. 79%,
= 0.02), higher Acute Physiology and Chronic Health Evaluation (APACHE II) score (23 vs. 19
= 0.0001), Charlson score (5.9 vs. 4.3,
= 0.001), mechanical ventilation (90% vs. 67%,
= 0.016), 28 days mortality (63% vs. 25%,
= 0.0001), and abnormal baseline creatinine (36% vs. 8%,
= 0.001). Coadministration of vancomycin had higher rates of nephrotoxicity (
= 0.039). There was no significant difference in nephrotoxicity between 6 and 9 MU/day dosing pattern (8.8% vs. 13.8%,
= 0.058).
Nephrotoxicity rate in our retrospective single center large series of patients receiving colistin was 13.1%. Patients with abnormal baseline creatinine, ICU stay, and higher disease severity are at higher risk of nephrotoxicity while on colistin. A daily dose of 9 million does not significantly increase nephrotoxicity compared to the 6 million. Concomitant administration of vancomycin with colistin increases the risk of nephrotoxicity. |
| doi_str_mv | 10.4103/ijccm.IJCCM_140_17 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5492736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A496485358</galeid><sourcerecordid>A496485358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-1b533b6c65518625b8035dda19dcf76320be0a05c77d9f84371dec09e8103feb3</originalsourceid><addsrcrecordid>eNptkkGP0zAQhS0EYsvCH-CAIiGhvaTYcZzYHJCqaGGLChwWJG6W40xaV47dtRPE_ntcdllaVPlgafy955nRQ-glwfOSYPrWbLUe5stPTfNZkhJLUj9CMyIEzykTPx6jGRZ1kbOiEGfoWYxbjItKFOQpOit4jQkv8QxdNd6aOBqXfYHdJvjR_zLajLdZqiy6yY7xXXZt3NpC1oAbA2QrFdaQXUMwELM--CFbus6o5-hJr2yEF_f3Ofr-4fJbc5Wvvn5cNotVrllVjTlpGaVtpSvGCK8K1nJMWdcpIjrd1xUtcAtYYabruhM9L2lNOtBYAE8T99DSc_T-znc3tQN0et-UsnIXzKDCrfTKyOMXZzZy7X9KVoqiplUyuLg3CP5mgjjKwUQN1ioHfoqSCMI5w6m3hL7-D936Kbg0XqIo41hUFP-j1sqCNK736V-9N5WLUlQlZwlNVH6CWoOD1KR30JtUPuLnJ_h0OhiMPil4cyDYgLLjJno7jca7eAwWd6AOPsYA_cPyCJb7YMk_wZKHwUqiV4drf5D8TRL9DWLZyJk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935809630</pqid></control><display><type>article</type><title>Colistin Nephrotoxicity in Adults: Single Centre Large Series from India</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ghafur, Abdul ; Gohel, Swati ; Devarajan, Vidyalakshmi ; Raja, T ; Easow, Jose ; Raja, M A ; Sreenivas, Sankar ; Ramakrishnan, Balasubramaniam ; Ramakrishnan, T ; Raman, S G ; Devaprasad, Dedeepiya ; Venkatachalam, Balaji ; Nimmagadda, Ramesh</creator><creatorcontrib>Ghafur, Abdul ; Gohel, Swati ; Devarajan, Vidyalakshmi ; Raja, T ; Easow, Jose ; Raja, M A ; Sreenivas, Sankar ; Ramakrishnan, Balasubramaniam ; Ramakrishnan, T ; Raman, S G ; Devaprasad, Dedeepiya ; Venkatachalam, Balaji ; Nimmagadda, Ramesh</creatorcontrib><description>Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect.
This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients.
Retrospective cohort study.
Case record analysis of patients who received colistin, in an oncology center in India, between January 2011 and December 2015. Nephrotoxicity was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria.
P < 0.05 was considered as statistically significant.
Out of the 229 patients, 13.1% (30/229) developed abnormal RIFLE. Abnormal RIFLE group (
= 30), in comparison to the normal renal function group (
= 199), had higher number of patients in intensive care unit (ICU) (96% vs. 79%,
= 0.02), higher Acute Physiology and Chronic Health Evaluation (APACHE II) score (23 vs. 19
= 0.0001), Charlson score (5.9 vs. 4.3,
= 0.001), mechanical ventilation (90% vs. 67%,
= 0.016), 28 days mortality (63% vs. 25%,
= 0.0001), and abnormal baseline creatinine (36% vs. 8%,
= 0.001). Coadministration of vancomycin had higher rates of nephrotoxicity (
= 0.039). There was no significant difference in nephrotoxicity between 6 and 9 MU/day dosing pattern (8.8% vs. 13.8%,
= 0.058).
Nephrotoxicity rate in our retrospective single center large series of patients receiving colistin was 13.1%. Patients with abnormal baseline creatinine, ICU stay, and higher disease severity are at higher risk of nephrotoxicity while on colistin. A daily dose of 9 million does not significantly increase nephrotoxicity compared to the 6 million. Concomitant administration of vancomycin with colistin increases the risk of nephrotoxicity.</description><identifier>ISSN: 0972-5229</identifier><identifier>EISSN: 1998-359X</identifier><identifier>DOI: 10.4103/ijccm.IJCCM_140_17</identifier><identifier>PMID: 28701840</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Antibiotics ; Bacteria ; Bacterial infections ; Cancer ; Colistin ; Drug dosages ; Drug resistance ; Gram-negative bacteria ; Health aspects ; Infectious diseases ; Intensive care ; Kidney diseases ; Mortality ; Nosocomial infections ; Oncology ; Prevalence studies (Epidemiology) ; Risk factors</subject><ispartof>Indian journal of critical care medicine, 2017-06, Vol.21 (6), p.350-354</ispartof><rights>COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt. Ltd. Jun 2017</rights><rights>Copyright: © 2017 Indian Journal of Critical Care Medicine 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-1b533b6c65518625b8035dda19dcf76320be0a05c77d9f84371dec09e8103feb3</citedby><cites>FETCH-LOGICAL-c566t-1b533b6c65518625b8035dda19dcf76320be0a05c77d9f84371dec09e8103feb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492736/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492736/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28701840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghafur, Abdul</creatorcontrib><creatorcontrib>Gohel, Swati</creatorcontrib><creatorcontrib>Devarajan, Vidyalakshmi</creatorcontrib><creatorcontrib>Raja, T</creatorcontrib><creatorcontrib>Easow, Jose</creatorcontrib><creatorcontrib>Raja, M A</creatorcontrib><creatorcontrib>Sreenivas, Sankar</creatorcontrib><creatorcontrib>Ramakrishnan, Balasubramaniam</creatorcontrib><creatorcontrib>Ramakrishnan, T</creatorcontrib><creatorcontrib>Raman, S G</creatorcontrib><creatorcontrib>Devaprasad, Dedeepiya</creatorcontrib><creatorcontrib>Venkatachalam, Balaji</creatorcontrib><creatorcontrib>Nimmagadda, Ramesh</creatorcontrib><title>Colistin Nephrotoxicity in Adults: Single Centre Large Series from India</title><title>Indian journal of critical care medicine</title><addtitle>Indian J Crit Care Med</addtitle><description>Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect.
This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients.
Retrospective cohort study.
Case record analysis of patients who received colistin, in an oncology center in India, between January 2011 and December 2015. Nephrotoxicity was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria.
P < 0.05 was considered as statistically significant.
Out of the 229 patients, 13.1% (30/229) developed abnormal RIFLE. Abnormal RIFLE group (
= 30), in comparison to the normal renal function group (
= 199), had higher number of patients in intensive care unit (ICU) (96% vs. 79%,
= 0.02), higher Acute Physiology and Chronic Health Evaluation (APACHE II) score (23 vs. 19
= 0.0001), Charlson score (5.9 vs. 4.3,
= 0.001), mechanical ventilation (90% vs. 67%,
= 0.016), 28 days mortality (63% vs. 25%,
= 0.0001), and abnormal baseline creatinine (36% vs. 8%,
= 0.001). Coadministration of vancomycin had higher rates of nephrotoxicity (
= 0.039). There was no significant difference in nephrotoxicity between 6 and 9 MU/day dosing pattern (8.8% vs. 13.8%,
= 0.058).
Nephrotoxicity rate in our retrospective single center large series of patients receiving colistin was 13.1%. Patients with abnormal baseline creatinine, ICU stay, and higher disease severity are at higher risk of nephrotoxicity while on colistin. A daily dose of 9 million does not significantly increase nephrotoxicity compared to the 6 million. Concomitant administration of vancomycin with colistin increases the risk of nephrotoxicity.</description><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Cancer</subject><subject>Colistin</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Gram-negative bacteria</subject><subject>Health aspects</subject><subject>Infectious diseases</subject><subject>Intensive care</subject><subject>Kidney diseases</subject><subject>Mortality</subject><subject>Nosocomial infections</subject><subject>Oncology</subject><subject>Prevalence studies (Epidemiology)</subject><subject>Risk factors</subject><issn>0972-5229</issn><issn>1998-359X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkkGP0zAQhS0EYsvCH-CAIiGhvaTYcZzYHJCqaGGLChwWJG6W40xaV47dtRPE_ntcdllaVPlgafy955nRQ-glwfOSYPrWbLUe5stPTfNZkhJLUj9CMyIEzykTPx6jGRZ1kbOiEGfoWYxbjItKFOQpOit4jQkv8QxdNd6aOBqXfYHdJvjR_zLajLdZqiy6yY7xXXZt3NpC1oAbA2QrFdaQXUMwELM--CFbus6o5-hJr2yEF_f3Ofr-4fJbc5Wvvn5cNotVrllVjTlpGaVtpSvGCK8K1nJMWdcpIjrd1xUtcAtYYabruhM9L2lNOtBYAE8T99DSc_T-znc3tQN0et-UsnIXzKDCrfTKyOMXZzZy7X9KVoqiplUyuLg3CP5mgjjKwUQN1ioHfoqSCMI5w6m3hL7-D936Kbg0XqIo41hUFP-j1sqCNK736V-9N5WLUlQlZwlNVH6CWoOD1KR30JtUPuLnJ_h0OhiMPil4cyDYgLLjJno7jca7eAwWd6AOPsYA_cPyCJb7YMk_wZKHwUqiV4drf5D8TRL9DWLZyJk</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Ghafur, Abdul</creator><creator>Gohel, Swati</creator><creator>Devarajan, Vidyalakshmi</creator><creator>Raja, T</creator><creator>Easow, Jose</creator><creator>Raja, M A</creator><creator>Sreenivas, Sankar</creator><creator>Ramakrishnan, Balasubramaniam</creator><creator>Ramakrishnan, T</creator><creator>Raman, S G</creator><creator>Devaprasad, Dedeepiya</creator><creator>Venkatachalam, Balaji</creator><creator>Nimmagadda, Ramesh</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Jaypee Brothers Medical Publishers Ltd</general><general>Medknow Publications & Media Pvt Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201706</creationdate><title>Colistin Nephrotoxicity in Adults: Single Centre Large Series from India</title><author>Ghafur, Abdul ; Gohel, Swati ; Devarajan, Vidyalakshmi ; Raja, T ; Easow, Jose ; Raja, M A ; Sreenivas, Sankar ; Ramakrishnan, Balasubramaniam ; Ramakrishnan, T ; Raman, S G ; Devaprasad, Dedeepiya ; Venkatachalam, Balaji ; Nimmagadda, Ramesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-1b533b6c65518625b8035dda19dcf76320be0a05c77d9f84371dec09e8103feb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Cancer</topic><topic>Colistin</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Gram-negative bacteria</topic><topic>Health aspects</topic><topic>Infectious diseases</topic><topic>Intensive care</topic><topic>Kidney diseases</topic><topic>Mortality</topic><topic>Nosocomial infections</topic><topic>Oncology</topic><topic>Prevalence studies (Epidemiology)</topic><topic>Risk factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Ghafur, Abdul</creatorcontrib><creatorcontrib>Gohel, Swati</creatorcontrib><creatorcontrib>Devarajan, Vidyalakshmi</creatorcontrib><creatorcontrib>Raja, T</creatorcontrib><creatorcontrib>Easow, Jose</creatorcontrib><creatorcontrib>Raja, M A</creatorcontrib><creatorcontrib>Sreenivas, Sankar</creatorcontrib><creatorcontrib>Ramakrishnan, Balasubramaniam</creatorcontrib><creatorcontrib>Ramakrishnan, T</creatorcontrib><creatorcontrib>Raman, S G</creatorcontrib><creatorcontrib>Devaprasad, Dedeepiya</creatorcontrib><creatorcontrib>Venkatachalam, Balaji</creatorcontrib><creatorcontrib>Nimmagadda, Ramesh</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghafur, Abdul</au><au>Gohel, Swati</au><au>Devarajan, Vidyalakshmi</au><au>Raja, T</au><au>Easow, Jose</au><au>Raja, M A</au><au>Sreenivas, Sankar</au><au>Ramakrishnan, Balasubramaniam</au><au>Ramakrishnan, T</au><au>Raman, S G</au><au>Devaprasad, Dedeepiya</au><au>Venkatachalam, Balaji</au><au>Nimmagadda, Ramesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Colistin Nephrotoxicity in Adults: Single Centre Large Series from India</atitle><jtitle>Indian journal of critical care medicine</jtitle><addtitle>Indian J Crit Care Med</addtitle><date>2017-06</date><risdate>2017</risdate><volume>21</volume><issue>6</issue><spage>350</spage><epage>354</epage><pages>350-354</pages><issn>0972-5229</issn><eissn>1998-359X</eissn><abstract>Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect.
This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients.
Retrospective cohort study.
Case record analysis of patients who received colistin, in an oncology center in India, between January 2011 and December 2015. Nephrotoxicity was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria.
P < 0.05 was considered as statistically significant.
Out of the 229 patients, 13.1% (30/229) developed abnormal RIFLE. Abnormal RIFLE group (
= 30), in comparison to the normal renal function group (
= 199), had higher number of patients in intensive care unit (ICU) (96% vs. 79%,
= 0.02), higher Acute Physiology and Chronic Health Evaluation (APACHE II) score (23 vs. 19
= 0.0001), Charlson score (5.9 vs. 4.3,
= 0.001), mechanical ventilation (90% vs. 67%,
= 0.016), 28 days mortality (63% vs. 25%,
= 0.0001), and abnormal baseline creatinine (36% vs. 8%,
= 0.001). Coadministration of vancomycin had higher rates of nephrotoxicity (
= 0.039). There was no significant difference in nephrotoxicity between 6 and 9 MU/day dosing pattern (8.8% vs. 13.8%,
= 0.058).
Nephrotoxicity rate in our retrospective single center large series of patients receiving colistin was 13.1%. Patients with abnormal baseline creatinine, ICU stay, and higher disease severity are at higher risk of nephrotoxicity while on colistin. A daily dose of 9 million does not significantly increase nephrotoxicity compared to the 6 million. Concomitant administration of vancomycin with colistin increases the risk of nephrotoxicity.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>28701840</pmid><doi>10.4103/ijccm.IJCCM_140_17</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0972-5229 |
| ispartof | Indian journal of critical care medicine, 2017-06, Vol.21 (6), p.350-354 |
| issn | 0972-5229 1998-359X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5492736 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antibiotics Bacteria Bacterial infections Cancer Colistin Drug dosages Drug resistance Gram-negative bacteria Health aspects Infectious diseases Intensive care Kidney diseases Mortality Nosocomial infections Oncology Prevalence studies (Epidemiology) Risk factors |
| title | Colistin Nephrotoxicity in Adults: Single Centre Large Series from India |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A38%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Colistin%20Nephrotoxicity%20in%20Adults:%20Single%20Centre%20Large%20Series%20from%20India&rft.jtitle=Indian%20journal%20of%20critical%20care%20medicine&rft.au=Ghafur,%20Abdul&rft.date=2017-06&rft.volume=21&rft.issue=6&rft.spage=350&rft.epage=354&rft.pages=350-354&rft.issn=0972-5229&rft.eissn=1998-359X&rft_id=info:doi/10.4103/ijccm.IJCCM_140_17&rft_dat=%3Cgale_pubme%3EA496485358%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935809630&rft_id=info:pmid/28701840&rft_galeid=A496485358&rfr_iscdi=true |